Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series Ltd: World’s leading Event Organizer

Back

Ana Falcon

Ana Falcon

National Center for Biotechnology (CNB-CSIC)

Title: Severe outcome in influenza virus infected patients is associated with reduced accumulation of defective viral genomes

Biography

PhD in Molecular Biology and Science PhD Award at Autonomous University, Madrid. During her scientific career, she has studied the molecular biology of several respiratory viruses of clinical significance as Influenza virus, SARS-CoV and other coronaviruses. She has worked on virus reverse genetics, functional analysis of viral and cellular proteins, molecular diagnosis of virus in clinical samples and on animal models to study viral pathogenesis. Her current research line is focused not only on the virus, but on the infected patient, and the role the contribution of virulence determinants and the patient play in the progression of the infection. To carry out these studies, she has stayed in several national and international research Centers and has collaborated with international groups and Health Institutions (Mount Sinai School of Medicine, New York, USA; Center for Diseases Control, CDC, Atlanta, USA; Center for Arrhythmia Research, Michigan USA; Institute of Health Carlos III, Madrid, Severo Ochoa Hospital, Madrid, others). She is developing and coordinating an international multidisciplinary project including physicians, microbiologists, molecular virologists and bioinformatics. She is Reviewer for several scientific journals and has trained PhD and Master students.

 

Abstract

Influenza A virus (IAV) infection can be severe or even lethal in toddlers, the elderly and patients with certain medical conditions. Infection of apparently healthy individuals nonetheless accounts for many severe disease cases and deaths, suggesting that viruses with increased pathogenicity co-circulate with pandemic or epidemic viruses. Looking for potential virulence factors, we have identified a viral genetic determinant that contributes to infection outcome. A polymerase mutation identified in a fatal IAV case, when introduced into two different recombinant virus backbones, led to reduced defective viral genomes (DGs) production and increased pathogenesis in mice. These data provide genetic support for the association of pathogenicity and low DGs accumulation induced by mutations present in pathogenic viruses circulating in humans. Testing this association, we performed a genomic analysis of viruses isolated from a cohort of previously healthy individuals who suffered highly severe IAV infection requiring admission to Intensive Care Unit, and patients with fatal outcome who additionally showed underlying medical conditions. These viruses were compared with those isolated from a cohort of mild IAV patients. Viruses from highly severe/fatal outcome patients showed significantly fewer DGs accumulation than control viruses, suggesting that low DGs abundance constitutes a new virulence viral pathogenic marker in humans, regardless of the mutations responsible.